AGE - AgeX Therapeutics, Inc.
After hours:
| Previous close | 0.5206 |
| Open | 0.5100 |
| Bid | 0.4900 x 1200 |
| Ask | 0.5500 x 800 |
| Day's range | 0.5020 - 0.5504 |
| 52-week range | 0.3720 - 0.8400 |
| Volume | |
| Avg. volume | 20,716 |
| Market cap | 20.888M |
| Beta (5Y monthly) | 1.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings date | 08 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireAgeX Therapeutics Announces Appeal of NYSE American Determination
ALAMEDA, Calif., May 23, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the "Exchange") indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii)
Business WireAgeX Therapeutics Reports First Quarter 2023 Financial Results
ALAMEDA, Calif., May 12, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.
Business WireAgeX Therapeutics Receives Stock Exchange Deficiency Letter
ALAMEDA, Calif., April 26, 2023--AgeX Therapeutics , Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has st
Business WireAgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
ALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.
Business WireAgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio
Business WireAgeX Therapeutics Reports Third Quarter 2022 Financial Results
ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.
Business WireAgeX Therapeutics Reports Second Quarter 2022 Financial Results
ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.